New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated

xlomafota13 shared this article with you from Inoreader New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated Via Association française pour l'étude du cancer Bull Cancer. 2021 Jun 22:S0007-4551(21)00175-2. doi: 10.1016/j.bulcan.2021.04.004. Online ahead of print. NO ABSTRACT PMID:34172272 | DOI:10.1016/j.bulcan.2021.04.004 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.